imiquimod has been researched along with Liver Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, Y; Ke, Y; Li, R; Liu, B; Liu, F; Liu, Q; Meng, F; Qian, L; Shao, J; Xu, R; Yu, L | 1 |
| Al Fayez, N; Böttger, R; Cullis, PR; Li, SD; Nguyen, A; Ong, CY; Rouhollahi, E; Witzigmann, D; Wu, J | 1 |
2 other study(ies) available for imiquimod and Liver Neoplasms
| Article | Year |
|---|---|
Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; CD4-Positive T-Lymphocytes; Female; Imiquimod; Immunologic Memory; Immunotherapy; Injections, Intralesional; Liver Neoplasms; Membrane Glycoproteins; Mice; Receptors, OX40; T-Lymphocytes; Toll-Like Receptor 7; Tumor Microenvironment; Vaccination | 2021 |
Hepatocyte-targeted delivery of imiquimod reduces hepatitis B virus surface antigen.
Topics: Adjuvants, Immunologic; Animals; Antigens, Surface; Antiviral Agents; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatocytes; Imiquimod; Interferon-alpha; Liver Neoplasms; Mice; Toll-Like Receptor 7; Unilamellar Liposomes | 2022 |